Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Juan C. Muruzabal"'
Autor:
Ignacio Zapardiel, Myriam Gracia Segovia, Ronalds Macuks, Rosanna Mancari, Patriciu Achimas-Cadariu, Giacomo Corrado, Arnoldas Bartusevicius, Vladyslav Sukhin, Juan C Muruzabal, Pluvio J Coronado Martín, Barbara Gardella, Jurgen M Piek, Nicole Concin, Clemente Arab, Dimitrios Papatheodorou, Stephan Polterauer, Sara Iacoponi, Teresa Nieto, Martha C Lopez-Sanclemente, Hanna Trukhan, Maria M Gil, Irina Bakinovskaya, Alena Dalamanava, Marc Cucurull, Dzmitry Rovski, Laura Baquedano, Luis Chiva, Marcin Mardas, Siarhei Anatolievich Mavrichev, Jaroslav Klat, Carlos A Lopez de la Manzanara, Yusuf Yildirim
Publikováno v:
International Journal of Gynecologic Cancer. :ijgc-2022
ObjectiveUterine sarcomas are a rare and heterogeneous group of malignancies that include different histological sub-types. The aim of this study was to identify and evaluate the impact of the different prognostic factors on overall survival and dise
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b5579fc5d3921a0afa5f18cbd838d13f
https://doi.org/10.1136/ijgc-2022-004204
https://doi.org/10.1136/ijgc-2022-004204
Autor:
Sandra Hervas-Stubbs, Ibon Tamayo-Uria, Pablo Sarobe, Uxua Mancheño, Antonio González-Martín, Edurne Elizalde, José Manuel Aramendía, Juan C. Muruzabal, Mariano Ponz-Sarvise, Francisco Guillén-Grima, Juan José Lasarte, Julia Alcaide, Enrique Conde, David Garcia-Ros, Carlos E. de Andrea, Diego Salas-Benito, José Ángel Mínguez, Jose Amores-Tirado
Publikováno v:
British Journal of Cancer
Background Adoptive immunotherapy with tumour-infiltrating lymphocytes (TIL) may benefit from the use of selective markers, such as PD-1, for tumour-specific T-cell enrichment, and the identification of predictive factors that help identify those pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8341aaeb56bee99355258a52e317e5a5
http://europepmc.org/articles/PMC7961070
http://europepmc.org/articles/PMC7961070
Autor:
Diego Salas-Benito, Enrique Conde, Ibon Tamayo-Uria, Uxua Mancheño, Edurne Elizalde, David Garcia-Ros, Jose M. Aramendia, Juan C. Muruzabal, Julia Alcaide, Francisco Guillen-Grima, Jose A. Minguez, Jose Amores-Tirado, Antonio Gonzalez-Martin, Pablo Sarobe, Juan J. Lasarte, Mariano Ponz-Sarvise, Carlos E. De Andrea, Sandra Hervas-Stubbs
Background: Adoptive immunotherapy with tumor-infiltrating lymphocytes (TIL) may benefit from the use of selective markers, such as programmed cell death protein 1 (PD-1), for tumor-specific T-cell enrichment, as well as predictive biomarkers that he
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7ec119d7cf271d8c737de45bd71cc08
https://doi.org/10.21203/rs.3.rs-25670/v1
https://doi.org/10.21203/rs.3.rs-25670/v1
